David Turveson (Cold Spring Harbor NY) #AACR23 A road map to defeat pancreatic cancer.
7:05am April 18th 2023 via Twitter Web App
Hudson #AACR23 Barriers to integration: knowledge or skills; communication from oncologist to PCP, EMRs variable, c… https://t.co/0RPorsXIl3
3:50pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Psychosocial issues - one is financial hardship by families. 22% material hardship, 30% coping/behav… https://t.co/MgnKYgaMvb
3:45pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Shows increasing adherence to recommended survivorship care, from 20% to about 40% now. Even though… https://t.co/6LOtrtmjHe
3:43pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Updated cardiomyopathy recommendations for surveillance. '23 ref https://t.co/ismGZwBHJR
3:39pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Second exemplar - anthracylin-related cardiotoxicity. Cardiac events and congestive heart failure in… https://t.co/YFxeX6tUWA
3:37pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Recommend now for BC pediatric survivors, yearly mammogram (beginning 8y after radiation or age 25 w… https://t.co/wBfi1GpLCq
3:35pm April 17th 2023 via Twitter Web App
Hudson #AACR23 After anthracyclines - 13x hazard ratio at the highest dosage; 15% risk of breast cancer at 50yo. Sh… https://t.co/QdoJl1LKxN
3:33pm April 17th 2023 via Twitter Web App
Hudson #AACR23 In breast cancer - cumulative incidence 13% - 20% by age 40-45y. As high as 35% by age 50. https://t.co/olnKb5w2cp
3:29pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Two exemplars to illustrate how high-risk groups have clinical risk prediction models and dev of int… https://t.co/7EBfnDsB74
3:27pm April 17th 2023 via Twitter Web App
Hudson #AACR23 With data, worked with IOM for guidelines to publish the first version in 2003, now on it's 5th edit… https://t.co/ugNTTrcIm4
3:25pm April 17th 2023 via Twitter Web App
Hudson #AACR23 After tracking for 50y, can relate Rx to late effects. Expanded now to genetic factors (BRCA, ATM, p… https://t.co/JvlXv09jP8
3:22pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Survivors by age 40 - 50 with at least one life-threatening condition. Shows a detailed, cumulative… https://t.co/uMbgIgXZf9
3:16pm April 17th 2023 via Twitter Web App
Hudson #AACR23 still plenty of life-altering late-effects; infertility, seizures, neurocognitive deficits, hearing/… https://t.co/jsadbE8LEE
3:13pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Late effects as a stimulus for change - now risk stratification of front-line cancer therapy, reduci… https://t.co/FM7wMY4VLU
3:12pm April 17th 2023 via Twitter Web App
Hudson #AACR23 Shows SEER data w/5y survival increasing: due to collab trials, understanding cancer pathobiology...… https://t.co/xgLFvvRHww
3:09pm April 17th 2023 via Twitter Web App
Melissa Hudson (St Jude Children's Res Hosp Memphis TN) #AACR23 AACR-Joseph Burchenal Award for outstanding achieve… https://t.co/dfvRIdvAxd
3:08pm April 17th 2023 via Twitter Web App
Fertig #AACR23 '16 Review - illustrating important points about sc analyses https://t.co/Lg50Ygkqak Finding domina… https://t.co/6SrYFhf1v5
8:57am April 17th 2023 via Twitter Web App
Fertig #AACR23 Review of Panc cancer - https://t.co/bcFtsse5ft Spatial proteomics maps immunosuppressive cells such… https://t.co/IzYga7YL75
8:54am April 17th 2023 via Twitter Web App
Fertig #AACR23 She comes from weather forecasting using math models. '21 ref https://t.co/70mUuWXyga
8:52am April 17th 2023 via Twitter Web App
Elana Fertig (Johns Hopkins MD USA) #AACR23 Forecasting pancreatic carcinogenesis through spatial multiomics. High-… https://t.co/MJj17tNElv
8:51am April 17th 2023 via Twitter Web App
Hwang #AACR23 Last section - technological advances to allow earlier detection. 37T cells in the body; 1T seconds =… https://t.co/gwWPKTACHo
8:44am April 17th 2023 via Twitter Web App
Hwang #AACR23 able to stain via MIBI-TOF 37-marker panel, from DCIS, Risom et al Cell 2021 https://t.co/7hpc5nXQ7i… https://t.co/OhiF9PMnHe
8:39am April 17th 2023 via Twitter Web App
Hwang #AACR23 Trends in incidence rates from SEER - incidence is flat - but is costly, ~$5B annually. But 'if it we… https://t.co/vf9HpFIx3t
8:35am April 17th 2023 via Twitter Web App
Hwang #AACR23 For prostate, thyroid, breast cancer: lifetime risk is 4%, 0.1%, 4% respectively. But the disease res… https://t.co/PGQMRFDiT3
8:32am April 17th 2023 via Twitter Web App
Hwang #AACR23 Stance was to be always treat it; natural history unknown. Defines overdiagnosis: 'of a disease that… https://t.co/LVEOVqhCUF
8:30am April 17th 2023 via Twitter Web App
Shelley Hwang (Duke Univ NC) #AACR23 When to intervene along the breast cancer continuum? Starts with DCIS - ducta… https://t.co/4yxPptnG7E
8:29am April 17th 2023 via Twitter Web App
Malkin #AACR23 For germline can look at somatic p53 mutations, CNV, methylation, fragmentome, etc from cfDNA in LFS… https://t.co/LhtvuFYVAC
7:36am April 17th 2023 via Twitter Web App
Malkin #AACR23 cfDNA analysis can be tailored to detect different t ypes of genome variation; "all are needed for h… https://t.co/wKobjlYo9m
7:34am April 17th 2023 via Twitter Web App
Malkin #AACR23 Pre-cancer event - in sporadic cancers - but this happens early, perhaps not that long 'after concep… https://t.co/lmPFwXY5ac
7:31am April 17th 2023 via Twitter Web App
Malkin #AACR23 1/2 show chromothripsis. Looked for a pattern of SNVs - had variants in one of the DNA pathway repai… https://t.co/RWPREIZejR
Malkin #AACR23 Found molecular signatures in Li-Fraumeni syndrome tumors; an aging signature found in all tumors; s… https://t.co/E8OHVE869M
7:28am April 17th 2023 via Twitter Web App
Malkin #AACR23 Can we learn something from the somatic genome? Li-Fraumeni Syndrome genome landscape, WGS analysis… https://t.co/kcrTUFGBZT
7:26am April 17th 2023 via Twitter Web App
Malkin #AACR23 Dx of pre-B ALL (masked hypodiploid), 5% MRD after induction (high risk protocol, bad news). After m… https://t.co/ch6Q835Neu
7:25am April 17th 2023 via Twitter Web App
Malkin #AACR23 p53 surveillance, around the world. Shows a 15yo female who was diagnosed pre-natal. Shows 'pre-symp… https://t.co/MDZrkjoE13
7:23am April 17th 2023 via Twitter Web App
Malkin #AACR23 There is a large Int'l replication repair deficiency consortia. Last example: Li-Fraumeni syndrome p… https://t.co/2hYWLqeBIU
7:21am April 17th 2023 via Twitter Web App
Malkin #AACR23 Shows OS data from this 2022 ref, with additional evidence (survival) in GBM; have to know the under… https://t.co/PJgQC4wOy4
7:20am April 17th 2023 via Twitter Web App
Malkin #AACR23 CMMRD tumors are 'attractive targets for ICI's' showing mutation burden across 7K cancers, dramatic… https://t.co/olByKGvAPh
7:18am April 17th 2023 via Twitter Web App
Malkin #AACR23 Outlines info about CMMRD from this ref https://t.co/P4AQyuwTov
7:16am April 17th 2023 via Twitter Web App
Malkin #AACR23 Shows the shift in fragment length in cancers. Shift to topic 2: mis-match repair syndrome. 5yo girl… https://t.co/b5xgIRKOsd
7:15am April 17th 2023 via Twitter Web App
Malkin #AACR23 For MPNST (pre-malignant disease), how do you rule it out? cfDNA 150-350bp fragments consistent with… https://t.co/EdpGn4Mtvr
7:12am April 17th 2023 via Twitter Web App
Malkin #AACR23 Results of Ph II trials of Sunitinib in children with PN: approved in CAN, showed 26/50 (56%) durabl… https://t.co/qmjclP4tlL
7:11am April 17th 2023 via Twitter Web App
Malkin #AACR23 Treatment targets in NF1: Farnesyltransferase inh; RTKi / Angiogenesis / TME; mTOR inh; MEK inh. "As… https://t.co/YBnQkv9dBp
7:09am April 17th 2023 via Twitter Web App
Malkin #AACR23 Shows malignant progression assoc'd with genetic evolution; accumulation events, biallelic loss of N… https://t.co/XPNR0XGOlD
7:08am April 17th 2023 via Twitter Web App
Malkin #AACR23 One of three context: Neurofibromatosis Type 1 (NF 1), 1:3500 freq single-gene disorder. Tumor dev,… https://t.co/RpvIsh4zhD
7:07am April 17th 2023 via Twitter Web App
Malkin #AACR23 Most findinds are new information; 78%, 22% previously known. Medulloblastoma - clinical outcome ass… https://t.co/FXbc5fYRNl
7:05am April 17th 2023 via Twitter Web App
Malkin #AACR23 Pediatric world is ahead of the adult oncology one: germline variants are common. Nature Cancer 2022… https://t.co/fGm4ZOzSaW
7:04am April 17th 2023 via Twitter Web App
Good morning! David Malkin (Univ Toronto CAN) #AACR23 Prediction and prevention: seeking the holy grail for cancer… https://t.co/IOJ9kQmIFh
7:02am April 17th 2023 via Twitter Web App
June #AACR23 CD2 CAR-T cell therapy have acceptable toxicity and efficacy in pediatric solid tumors.… https://t.co/kr3ZCZewNm
5:08pm April 16th 2023 via Twitter Web App
June #AACR23 With Human T-cells, many genes to knock out - shows a list of 30 genes, to address many issues in soli… https://t.co/NqFP6qodzs
5:06pm April 16th 2023 via Twitter Web App